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The letters from Nanra and Lornoy et al claim that
the incidence of analgesic nephropathy (AN) would be
To the Editor: The article in the December 2000 issue controlled not by an isolated phenacetin withdrawal, but
of Kidney International by the Ad Hoc Committee of the by a ban on all combined analgesics. Nanra’s conclusion,
International Study Group on Analgesics and Nephropa- however, was based on short-term observations in a lim-
thy [1] questions the harmful impact of nonphenacetin- ited number of patients [1]. In Australia, phenacetin
containing analgesic mixtures on the kidneys. We won- was progressively withdrawn from the abused brands of
der whether there is a need for these combinations at
analgesics, and its sale was legally prohibited in 1977.all. APC brands have never been proven to be effective
Two years later, the sales of all combined analgesicsfor the indication of chronic pain treatment. The intro-
were also restricted. Because the renal consequences ofduction of these formulations is based on an irrational
phenacetin may not occur until many years after intakeguiding principle presented by Buergi in 1927 (references
has ceased, the limited follow-up after phenacetin with-in [2]). The German view is (1) almost none of the single
drawal alone does not allow its effects to be separatedanalgesics (not even phenacetin) have been taken regu-
from those of the later withdrawal of combined analge-larly in amounts reached by mixed compounds; and (2)
since over-the-counter analgesic compounds have never sics. Theoretical speculations, such as those about the
been sold without caffeine (20 to 50 mg per unit) and toxicity of paracetamol, can only suggest hypotheses. All
since low-dose caffeine alone is not effective for pain the proposed hypotheses, however, should be (but have
relief (with the exception of caffeine-withdrawal–induced not been) compatible with the evidence that the incidence
headache), why is it still used? of AN decreased similarly, in both Belgium and Australia,
Our study provides evidence that, besides phenacetin, despite persistently high consumption of mixed non-
paracetamol-containing mixtures do increase the risk of
phenacetin analgesics in Belgium [2, 3].end-stage renal disease [3]. Because risk estimates are
Lornoy et al state that the incidence of AN in their di-based on hospital controls, the specific risks for the gen-
alysis unit correlated better with the withdrawal of non-eral population may be even higher. Detrimental renal
phenacetin analgesics than with the withdrawal of phen-effects of high-dose paracetamol exposure are well docu-
acetin. Because AN is not evenly distributed by geographicmented in both clinical and experimental studies [sum-
region, however, local incidence data are influenced bymarized in 4, 5].
Warnings about the adverse effects of phenacetin changes in recruitment of patients for dialysis due to a
and nonphenacetin-containing compounds have been changing pattern of referral by local nephrologists and/or
ignored for a long time [6]. The debate continues, why to the opening of new regional dialysis units. The data
and for what? in the figure by Lornoy et al do not show the expected
progressive increase in the total number of patients ad-Wolfgang Pommer and Eberhard Greiser
Berlin, Germany mitted for dialysis and are most consistent with a change
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in recruitment. These data from a single center are there- tific evidence to associate nonphenacetin-combined anal-
fore inadequate to conclude if and when a change oc- gesics with nephropathy, the Committee members had
curred in the incidence of AN in the region. Another prob- to conclude that such evidence is absent. Patients can
lem in their study is that they considered only the only benefit from satisfactory scientific data collected
changed composition of a single analgesic brand from in well-performed clinical studies. Unfortunately, such
which phenacetin was withdrawn in 1972, but they omit- studies on this topic do not yet exist.
ted the second frequently abused brand from which In their presentation of “the German view,” Pommer
phenacetin was withdrawn in 1981 [4]. These two brands and Greiser offer a distorted picture. They do not re-
became single analgesics in 1989, but their sales had spond to the methodologic defects noted in our analysis
decreased progressively, while the sale of another non- of their own study. Their comments about caffeine were
phenacetin-mixed analgesic increased markedly. The in- answered in a recent report by a separate ad hoc commit-
crease in consumption of this nonphenacetin-mixed anal- tee [7]. The review they cite by Blantz concluded that
gesic obviously did not prevent the decrease in the “epidemiologic studies in healthy individuals have failed
incidence of AN. to demonstrate a significant correlation between APAP
The Committee members discussed in detail the work (paracetamol) use and chronic renal disease and classic
of Elseviers and De Broe concerning the nephrotoxicity
analgesic nephropathy.” In Porter’s cited review of ani-
of nonphenacetin analgesics, and our negative conclu-
mal experiments, aspirin seemed to be the most nephro-sions are not refuted in the Elseviers and De Broe letter.
toxic of the commonly available analgesics.The Committee members did not believe it useful to list
None of the comments in these four letters alters orall their publications on the subject, since most refer
even suitably addresses our original statement that “into already published data. Their three papers on the
the limited amount of experimental pharmacologicalsignificance of renal imaging for the diagnosis of AN
data in humans and animals, the committee found nowere not included in our reference list because the essen-
convincing evidence to confirm or refute the hypothesistial data appear in their two overview articles [5, 6],
that nonphenacetin combined analgesics are more dan-which were cited as our references 11 and 12. A full
gerous than single formulations.” The epidemiologic re-discussion of their diagnostic criteria was deemed super-
search needed to answer this question has yet to be done.fluous since they provide no new data on the analgesic/
nephropathy relationship. To validate the diagnosis of
Alvan R. Feinstein, for the members of the Ad HocAN based on CT scan, Elseviers and De Broe used as
Committee (in alphabetical order): Gary C. Curhan,
criterion the diagnosis made by the local nephrologists. Elizabeth Delzell, Paul J. DeSchepper, Johannes M. Fox,
Nephrologists diagnose AN on the basis of the history Helmut Graf, Lothar A.J. Heinemann, Friedrich C. Luft,
Paul Michielsen, Michael J. Mihatsch, Samy Suissa,of abuse, the clinical evolution, the volume of the kid-
Fokko van der Woude, and Stefan Willichneys, and direct or indirect evidence of papillary necrosis.
None of these features is specific to AN. As the volume Correspondence to Alvan R. Feinstein, M.D., Departments of Medi-
of the kidneys and papillary necrosis are also included cine and Epidemiology, Yale University School of Medicine, 333 Cedar
Street, New Haven, CT 06510, USA.in the nephrologists’ criteria, it is not surprising to find a
E-mail: alvan.feinstein@yale.edugood correlation with the CT scan. Contrary to the impli-
cations by Elseviers and De Broe, however, the value
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Acta Clin Belg 53:311–318, 1998logic examination could bring a definitive answer. Capil-
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